Spyre Therapeutics Added to the Nasdaq Biotechnology Index

PR NewswireDec 18 21:00

LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50

Futu NewsDec 18 06:31 · Ratings

BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $70

Futu NewsDec 18 03:31 · Ratings

Promising Potential of Spyre Therapeutics' SPY002 Drives Buy Rating Amid Robust Anti-TL1A Market

TipRanksDec 18 03:15 · Ratings

Spyre Therapeutics Analyst Ratings

BenzingaDec 11 19:30 · Ratings

JonesTrading Initiates Spyre Therapeutics(SYRE.US) With Hold Rating

Futu NewsDec 11 05:31 · Ratings